Daniel Ebner
Group Head / PI and Member of congregation
The High Throughput Screening Facility is a major component of the Target Discovery Institute (or TDI) which is a new research centre initiated by the Nuffield Department of Medicine and the University of Oxford with a mandate to develop new target screening methodologies, investigate disease pathways as a means for identifying 'drug targets' and advance therapeutically relevant targets for drug development.
The aim of the high throughput screening facility at the TDI is to provide research scientists with access to a comprehensive, cost-effective facility capable of running high throughput cell based small compound and RNAi screens as well as biochemical small compound screens
Recent publications
-
Continuous population-level monitoring of SARS-CoV-2 seroprevalence in a large European metropolitan region.
Journal article
Emmenegger M. et al, (2023), iScience
-
A genome-wide CRISPR screen identifies CALCOCO2 as a regulator of beta cell function influencing type 2 diabetes risk.
Journal article
Rottner AK. et al, (2022), Nat Genet
-
SARS-CoV-2 antibody trajectories after a single COVID-19 vaccination with and without prior infection.
Journal article
Wei J. et al, (2022), Nat Commun, 13
-
Automated 96-well format high throughput colony formation assay for siRNA library screen.
Journal article
Hatch SB. et al, (2022), STAR Protoc, 3
-
Antibody responses and correlates of protection in the general population after two doses of the ChAdOx1 or BNT162b2 vaccines.
Journal article
Wei J. et al, (2022), Nat Med, 28, 1072 - 1082